Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Rating of “Hold” from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given a consensus rating of “Hold” by the eight research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $74.1667.

Several equities research analysts recently commented on LNTH shares. Truist Financial reaffirmed a “hold” rating and issued a $61.00 price objective (down from $63.00) on shares of Lantheus in a research report on Monday, November 10th. JMP Securities dropped their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. B. Riley cut their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. Mizuho reduced their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Finally, TD Cowen decreased their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th.

Institutional Trading of Lantheus

A number of institutional investors have recently made changes to their positions in the business. Harbor Capital Advisors Inc. raised its stake in Lantheus by 24.7% in the second quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock valued at $15,554,000 after buying an additional 37,691 shares during the period. Reinhart Partners LLC. boosted its stake in shares of Lantheus by 16.4% during the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after acquiring an additional 197,719 shares during the period. Swedbank AB increased its holdings in shares of Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after acquiring an additional 121,500 shares during the last quarter. Strs Ohio acquired a new position in shares of Lantheus during the 1st quarter worth approximately $4,529,000. Finally, Select Equity Group L.P. raised its stake in Lantheus by 899.2% in the 1st quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider’s stock valued at $9,842,000 after acquiring an additional 90,751 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $61.87 on Friday. The business has a 50 day simple moving average of $55.24 and a 200 day simple moving average of $63.71. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of 26.00 and a beta of -0.10.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. Analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.